Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia
NCT ID: NCT04948008
Last Updated: 2021-07-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2/PHASE3
Total Enrollment
8 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-11-05
Study Completion Date
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
IBI306 is a bio-innovative drug against proprotein convertase subtilisin 9 (PCSK-9) monoclonal antibody. Currently, cholesterol-lowering drugs with multiple mechanisms of action are on the market or under development. Among them, anti-PCSK-9 monoclonal antibodies have received widespread attention due to their good safety and efficacy. The results of existing preclinical studies show that IBI306 has a clear structure, good stability, and is not inferior to other drugs of its kind in terms of drug activity, animal pharmacokinetics (PK)/pharmacodynamics (PD) and safety.
This study is divided into two phases: the dose exploration phase (the first phase) and the confirmatory phase (the second phase). Each stage is divided into screening period, treatment period, and safety follow-up period. The first phase of this research is the randomized design of open labels. The second stage is an open, single-arm design.
The main purpose of the first phase of the study: to evaluate the tolerability and safety of multiple-dose repeated administration of IBI306 in the Chinese population with hypercholesterolemia, and to recommend the dose for the second phase. The main purpose of the second phase of the study: to evaluate the effectiveness of IBI306 in the Chinese homozygous familial hypercholesterolemia population. Secondary research purpose: To evaluate the safety and immunogenicity of IBI306 in Chinese homozygous familial hypercholesterolemia population.
This study is divided into two phases: the dose exploration phase (the first phase) and the confirmatory phase (the second phase). Each stage is divided into screening period, treatment period, and safety follow-up period. The first phase of this research is the randomized design of open labels. The second stage is an open, single-arm design.
The main purpose of the first phase of the study: to evaluate the tolerability and safety of multiple-dose repeated administration of IBI306 in the Chinese population with hypercholesterolemia, and to recommend the dose for the second phase. The main purpose of the second phase of the study: to evaluate the effectiveness of IBI306 in the Chinese homozygous familial hypercholesterolemia population. Secondary research purpose: To evaluate the safety and immunogenicity of IBI306 in Chinese homozygous familial hypercholesterolemia population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
NCT04289285
Hypercholesterolemia
COMPLETED
PHASE3
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
NCT04031742
Homozygous Familial Hypercholesterolemia
COMPLETED
PHASE2/PHASE3
Integrated Biomarker And Imaging Study - 2
NCT00268996
Atherosclerosis
COMPLETED
PHASE2
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers
NCT02057835
Healthy
COMPLETED
PHASE1
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
NCT06572267
Coronary Artery Disease
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion Criteria
1. Provide a signed and dated informed consent form.
2. Men or women aged ≥18 and ≤80 at the time of screening.
3. Weight ≥40 kg at the time of screening.
4. Meet at least one of genetic testing confirmation or clinical data to diagnose homozygous familial hypercholesterolemia.
Clinical diagnosis basis: based on untreated LDL-C concentration\> 13 mmol/L or after treatment (defined as receiving moderate-strength or maximum tolerated dose of statin for at least 4 weeks, with or without ezetimibe ) LDL-C concentration\> 8mmol/L, and xanthoma occurred before the age of 10 or both parents have a history of heterozygous familial hypercholesterolemia.
5. Maintain a low-fat diet and stably take the current lipid-lowering therapy (taking moderate-strength statins, except for statin intolerance, with or without ezetimibe, bile acid chelator, or niacin) for at least 4 weeks.
6. The fasting LDL cholesterol concentration of the local laboratory at the time of screening was ≥3.4 mmol/L.
7. Fasting triglycerides ≤4.5 mmol/L during screening by the local laboratory.
8. The subjects indicated their willingness and cooperation to complete all the steps in the research and the research intervention period.
Exclusion criteria
1. Dialysis or plasma exchange was performed within 8 weeks before screening.
2. Patients who have received liver transplant surgery in the past.
3. Have used Mipomethamine or Lometapide within 5 months before screening.
4. Subjects should adjust their current lipid-lowering drug regimen or doses such as statins within 4 weeks before screening (these subjects can stabilize the current dose of lipid-lowering drugs such as statins and can be re-screened for 1 month).
5. There are uncontrolled clinical diseases that may affect blood lipids or lipoprotein levels (for patients with thyroid hormone replacement therapy, the thyroid hormone dose needs to be stabilized for at least 6 weeks before the screening visit)
6. New York Heart Association (NYHA) grade III or IV heart failure, or recently detected left ventricular ejection fraction \<30%.
7. Uncontrolled severe arrhythmia, defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response or supraventricular tachycardia.
8. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting or stroke occurred within 3 months before enrollment.
9. Plan to have heart surgery or revascularization within 20 weeks after screening.
10. Poorly controlled hypertension is defined as a systolic blood pressure\> 180 mmHg or a diastolic blood pressure\> 110 mmHg confirmed by repeated measurements.
11. Moderate to severe renal insufficiency, defined as the estimated glomerular filtration rate \<30 ml/min/1.73m2 during the screening period, calculated using the MDRD formula: eGFR =186 x SCr (mg/dl)-1.154x (age )-0.203x (0.742 \[if female\]), the unit conversion of blood creatinine: 1μmol/L=0.0113 mg/d.
12. Active liver disease or liver function impairment is defined as the screening period determined by local laboratory analysis, aspartate aminotransferase or alanine aminotransferase\> 3 times the upper limit of normal (ULN).
13. Creatine kinase (CK) ≥ 5 times of ULN during screening, confirmed by repeated measurements at least 1 week apart.
14. As judged by the investigator, there is a known active infection or major blood, kidney, metabolic, gastrointestinal or endocrine dysfunction.
15. Diagnosed deep vein thrombosis or pulmonary embolism within 3 months before enrollment.
16. Except for those who have been sterilized or menopausal, female subjects with potential for pregnancy, if they are unwilling to inform their sexual partners to participate in the clinical study, and take effective measures during the use of the study drug and within 15 weeks after the last dose of the study drug Contraceptive measures. Male subjects are unwilling to inform their female sexual partners that they participate in the clinical study.
17. Subjects who are pregnant or breastfeeding, or planning to become pregnant or breastfeeding during the period of study medication or within 15 weeks after the last dose of study medication.
18. Suffered from malignant tumors in the past 5 years (except for non-melanoma skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast or stage 1 prostate cancer).
19. Human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies or syphilis antibodies were positive at the time of screening.
20. The subject has been treated with a PCSK9 inhibitor or participated in other studies that inhibit PCSK9.
21. Known allergy to study drug and its ingredients.
22. Those who are judged by the investigator to be unsuitable to participate in the study (for example, alcohol or other drug abuse, inability or unwillingness to comply with the agreement, or mental illness).
23. Currently participating in another medical device or drug research, or the previous medical device or drug clinical research has ended, but the last time to receive other research drugs is within 30 days of screening.
24. In any other circumstances, the investigator or the sponsor after discussing it may impair the subject's ability or safety to give written informed consent and/or comply with all necessary research procedures.
1. Provide a signed and dated informed consent form.
2. Men or women aged ≥18 and ≤80 at the time of screening.
3. Weight ≥40 kg at the time of screening.
4. Meet at least one of genetic testing confirmation or clinical data to diagnose homozygous familial hypercholesterolemia.
Clinical diagnosis basis: based on untreated LDL-C concentration\> 13 mmol/L or after treatment (defined as receiving moderate-strength or maximum tolerated dose of statin for at least 4 weeks, with or without ezetimibe ) LDL-C concentration\> 8mmol/L, and xanthoma occurred before the age of 10 or both parents have a history of heterozygous familial hypercholesterolemia.
5. Maintain a low-fat diet and stably take the current lipid-lowering therapy (taking moderate-strength statins, except for statin intolerance, with or without ezetimibe, bile acid chelator, or niacin) for at least 4 weeks.
6. The fasting LDL cholesterol concentration of the local laboratory at the time of screening was ≥3.4 mmol/L.
7. Fasting triglycerides ≤4.5 mmol/L during screening by the local laboratory.
8. The subjects indicated their willingness and cooperation to complete all the steps in the research and the research intervention period.
Exclusion criteria
1. Dialysis or plasma exchange was performed within 8 weeks before screening.
2. Patients who have received liver transplant surgery in the past.
3. Have used Mipomethamine or Lometapide within 5 months before screening.
4. Subjects should adjust their current lipid-lowering drug regimen or doses such as statins within 4 weeks before screening (these subjects can stabilize the current dose of lipid-lowering drugs such as statins and can be re-screened for 1 month).
5. There are uncontrolled clinical diseases that may affect blood lipids or lipoprotein levels (for patients with thyroid hormone replacement therapy, the thyroid hormone dose needs to be stabilized for at least 6 weeks before the screening visit)
6. New York Heart Association (NYHA) grade III or IV heart failure, or recently detected left ventricular ejection fraction \<30%.
7. Uncontrolled severe arrhythmia, defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response or supraventricular tachycardia.
8. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting or stroke occurred within 3 months before enrollment.
9. Plan to have heart surgery or revascularization within 20 weeks after screening.
10. Poorly controlled hypertension is defined as a systolic blood pressure\> 180 mmHg or a diastolic blood pressure\> 110 mmHg confirmed by repeated measurements.
11. Moderate to severe renal insufficiency, defined as the estimated glomerular filtration rate \<30 ml/min/1.73m2 during the screening period, calculated using the MDRD formula: eGFR =186 x SCr (mg/dl)-1.154x (age )-0.203x (0.742 \[if female\]), the unit conversion of blood creatinine: 1μmol/L=0.0113 mg/d.
12. Active liver disease or liver function impairment is defined as the screening period determined by local laboratory analysis, aspartate aminotransferase or alanine aminotransferase\> 3 times the upper limit of normal (ULN).
13. Creatine kinase (CK) ≥ 5 times of ULN during screening, confirmed by repeated measurements at least 1 week apart.
14. As judged by the investigator, there is a known active infection or major blood, kidney, metabolic, gastrointestinal or endocrine dysfunction.
15. Diagnosed deep vein thrombosis or pulmonary embolism within 3 months before enrollment.
16. Except for those who have been sterilized or menopausal, female subjects with potential for pregnancy, if they are unwilling to inform their sexual partners to participate in the clinical study, and take effective measures during the use of the study drug and within 15 weeks after the last dose of the study drug Contraceptive measures. Male subjects are unwilling to inform their female sexual partners that they participate in the clinical study.
17. Subjects who are pregnant or breastfeeding, or planning to become pregnant or breastfeeding during the period of study medication or within 15 weeks after the last dose of study medication.
18. Suffered from malignant tumors in the past 5 years (except for non-melanoma skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast or stage 1 prostate cancer).
19. Human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies or syphilis antibodies were positive at the time of screening.
20. The subject has been treated with a PCSK9 inhibitor or participated in other studies that inhibit PCSK9.
21. Known allergy to study drug and its ingredients.
22. Those who are judged by the investigator to be unsuitable to participate in the study (for example, alcohol or other drug abuse, inability or unwillingness to comply with the agreement, or mental illness).
23. Currently participating in another medical device or drug research, or the previous medical device or drug clinical research has ended, but the last time to receive other research drugs is within 30 days of screening.
24. In any other circumstances, the investigator or the sponsor after discussing it may impair the subject's ability or safety to give written informed consent and/or comply with all necessary research procedures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Familial Hypercholesterolemia - Homozygous
Lipid Metabolism Disorders
Proprotein Convertase Subtilisin/Kexin 9
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
The first phase of this research is the randomized design of open labels. The second stage is an open, single-arm design.
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group 1
The subjects received IBI306 150 mg Q2W subcutaneously injected into the abdomen each time for 12 weeks;
Group Type
EXPERIMENTAL
IBI306
Intervention Type
BIOLOGICAL
IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
Treatment group 2
The subjects received IBI306 300 mg Q4W subcutaneously injected into the abdomen each time for 12 weeks;
Group Type
EXPERIMENTAL
IBI306
Intervention Type
BIOLOGICAL
IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IBI306
IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provide a signed and dated informed consent form.
2. Men or women aged ≥18 and ≤80 at the time of screening.
3. Weight ≥40 kg at the time of screening.
4. Meet at least one of genetic testing confirmation or clinical data to diagnose homozygous familial hypercholesterolemia.
Clinical diagnosis basis: based on untreated LDL-C concentration\> 13 mmol/L or after treatment (defined as receiving moderate-strength or maximum tolerated dose of statin for at least 4 weeks, with or without ezetimibe ) LDL-C concentration\> 8mmol/L, and xanthoma occurred before the age of 10 or both parents have a history of heterozygous familial hypercholesterolemia.
5. Maintain a low-fat diet and stably take the current lipid-lowering therapy (taking moderate-strength statins, except for statin intolerance, with or without ezetimibe, bile acid chelator, or niacin) for at least 4 weeks.
6. The fasting LDL cholesterol concentration of the local laboratory at the time of screening was ≥3.4 mmol/L.
7. Fasting triglycerides ≤4.5 mmol/L during screening by the local laboratory.
8. The subjects indicated their willingness and cooperation to complete all the steps in the research and the research intervention period.
\-
2. Men or women aged ≥18 and ≤80 at the time of screening.
3. Weight ≥40 kg at the time of screening.
4. Meet at least one of genetic testing confirmation or clinical data to diagnose homozygous familial hypercholesterolemia.
Clinical diagnosis basis: based on untreated LDL-C concentration\> 13 mmol/L or after treatment (defined as receiving moderate-strength or maximum tolerated dose of statin for at least 4 weeks, with or without ezetimibe ) LDL-C concentration\> 8mmol/L, and xanthoma occurred before the age of 10 or both parents have a history of heterozygous familial hypercholesterolemia.
5. Maintain a low-fat diet and stably take the current lipid-lowering therapy (taking moderate-strength statins, except for statin intolerance, with or without ezetimibe, bile acid chelator, or niacin) for at least 4 weeks.
6. The fasting LDL cholesterol concentration of the local laboratory at the time of screening was ≥3.4 mmol/L.
7. Fasting triglycerides ≤4.5 mmol/L during screening by the local laboratory.
8. The subjects indicated their willingness and cooperation to complete all the steps in the research and the research intervention period.
\-
Exclusion Criteria
1. Dialysis or plasma exchange was performed within 8 weeks before screening.
2. Patients who have received liver transplant surgery in the past.
3. Have used Mipomethamine or Lometapide within 5 months before screening.
4. Subjects should adjust their current lipid-lowering drug regimen or doses such as statins within 4 weeks before screening (these subjects can stabilize the current dose of lipid-lowering drugs such as statins and can be re-screened for 1 month).
5. There are uncontrolled clinical diseases that may affect blood lipids or lipoprotein levels (for patients with thyroid hormone replacement therapy, the thyroid hormone dose needs to be stabilized for at least 6 weeks before the screening visit)
6. New York Heart Association (NYHA) grade III or IV heart failure, or recently detected left ventricular ejection fraction \<30%.
7. Uncontrolled severe arrhythmia, defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response or supraventricular tachycardia.
8. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting or stroke occurred within 3 months before enrollment.
9. Plan to have heart surgery or revascularization within 20 weeks after screening.
10. Poorly controlled hypertension is defined as a systolic blood pressure\> 180 mmHg or a diastolic blood pressure\> 110 mmHg confirmed by repeated measurements.
11. Moderate to severe renal insufficiency, defined as the estimated glomerular filtration rate \<30 ml/min/1.73m2 during the screening period, calculated using the MDRD formula: eGFR =186 x SCr (mg/dl)-1.154x (age )-0.203x (0.742 \[if female\]), the unit conversion of blood creatinine: 1μmol/L=0.0113 mg/d.
12. Active liver disease or liver function impairment is defined as the screening period determined by local laboratory analysis, aspartate aminotransferase or alanine aminotransferase\> 3 times the upper limit of normal (ULN).
13. Creatine kinase (CK) ≥ 5 times of ULN during screening, confirmed by repeated measurements at least 1 week apart.
14. As judged by the investigator, there is a known active infection or major blood, kidney, metabolic, gastrointestinal or endocrine dysfunction.
15. Diagnosed deep vein thrombosis or pulmonary embolism within 3 months before enrollment.
16. Except for those who have been sterilized or menopausal, female subjects with potential for pregnancy, if they are unwilling to inform their sexual partners to participate in the clinical study, and take effective measures during the use of the study drug and within 15 weeks after the last dose of the study drug Contraceptive measures. Male subjects are unwilling to inform their female sexual partners that they participate in the clinical study.
17. Subjects who are pregnant or breastfeeding, or planning to become pregnant or breastfeeding during the period of study medication or within 15 weeks after the last dose of study medication.
18. Suffered from malignant tumors in the past 5 years (except for non-melanoma skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast or stage 1 prostate cancer).
19. Human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies or syphilis antibodies were positive at the time of screening.
20. The subject has been treated with a PCSK9 inhibitor or participated in other studies that inhibit PCSK9.
21. Known allergy to study drug and its ingredients.
22. Those who are judged by the investigator to be unsuitable to participate in the study (for example, alcohol or other drug abuse, inability or unwillingness to comply with the agreement, or mental illness).
23. Currently participating in another medical device or drug research, or the previous medical device or drug clinical research has ended, but the last time to receive other research drugs is within 30 days of screening.
24. In any other circumstances, the investigator or the sponsor after discussing it may impair the subject's ability or safety to give written informed consent and/or comply with all necessary research procedures.
2. Patients who have received liver transplant surgery in the past.
3. Have used Mipomethamine or Lometapide within 5 months before screening.
4. Subjects should adjust their current lipid-lowering drug regimen or doses such as statins within 4 weeks before screening (these subjects can stabilize the current dose of lipid-lowering drugs such as statins and can be re-screened for 1 month).
5. There are uncontrolled clinical diseases that may affect blood lipids or lipoprotein levels (for patients with thyroid hormone replacement therapy, the thyroid hormone dose needs to be stabilized for at least 6 weeks before the screening visit)
6. New York Heart Association (NYHA) grade III or IV heart failure, or recently detected left ventricular ejection fraction \<30%.
7. Uncontrolled severe arrhythmia, defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response or supraventricular tachycardia.
8. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting or stroke occurred within 3 months before enrollment.
9. Plan to have heart surgery or revascularization within 20 weeks after screening.
10. Poorly controlled hypertension is defined as a systolic blood pressure\> 180 mmHg or a diastolic blood pressure\> 110 mmHg confirmed by repeated measurements.
11. Moderate to severe renal insufficiency, defined as the estimated glomerular filtration rate \<30 ml/min/1.73m2 during the screening period, calculated using the MDRD formula: eGFR =186 x SCr (mg/dl)-1.154x (age )-0.203x (0.742 \[if female\]), the unit conversion of blood creatinine: 1μmol/L=0.0113 mg/d.
12. Active liver disease or liver function impairment is defined as the screening period determined by local laboratory analysis, aspartate aminotransferase or alanine aminotransferase\> 3 times the upper limit of normal (ULN).
13. Creatine kinase (CK) ≥ 5 times of ULN during screening, confirmed by repeated measurements at least 1 week apart.
14. As judged by the investigator, there is a known active infection or major blood, kidney, metabolic, gastrointestinal or endocrine dysfunction.
15. Diagnosed deep vein thrombosis or pulmonary embolism within 3 months before enrollment.
16. Except for those who have been sterilized or menopausal, female subjects with potential for pregnancy, if they are unwilling to inform their sexual partners to participate in the clinical study, and take effective measures during the use of the study drug and within 15 weeks after the last dose of the study drug Contraceptive measures. Male subjects are unwilling to inform their female sexual partners that they participate in the clinical study.
17. Subjects who are pregnant or breastfeeding, or planning to become pregnant or breastfeeding during the period of study medication or within 15 weeks after the last dose of study medication.
18. Suffered from malignant tumors in the past 5 years (except for non-melanoma skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast or stage 1 prostate cancer).
19. Human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies or syphilis antibodies were positive at the time of screening.
20. The subject has been treated with a PCSK9 inhibitor or participated in other studies that inhibit PCSK9.
21. Known allergy to study drug and its ingredients.
22. Those who are judged by the investigator to be unsuitable to participate in the study (for example, alcohol or other drug abuse, inability or unwillingness to comply with the agreement, or mental illness).
23. Currently participating in another medical device or drug research, or the previous medical device or drug clinical research has ended, but the last time to receive other research drugs is within 30 days of screening.
24. In any other circumstances, the investigator or the sponsor after discussing it may impair the subject's ability or safety to give written informed consent and/or comply with all necessary research procedures.
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen People's Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
dong shaohong, doctor
Role: STUDY_CHAIR
Shenzhen People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
xili People's Hospital
Shenzhen, Guangdong, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LQY-PCSK9-Homozygous
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
NCT05976893
NOT_YET_RECRUITING
PHASE4
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
NCT07091929
COMPLETED
PHASE1
Darapladib China PK
NCT02000804
COMPLETED
PHASE1
Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease
NCT02294994
UNKNOWN
PHASE4
Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography
NCT04338165
UNKNOWN
PHASE2
Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients
NCT05549336
UNKNOWN
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
NCT01975376
TERMINATED
PHASE3
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
NCT01975389
TERMINATED
PHASE3
To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
NCT02601560
COMPLETED
PHASE2
A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
NCT06816264
COMPLETED
PHASE2
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740
RECRUITING
PHASE4
SB-480848 In Subjects With Coronary Heart Disease
NCT00269048
COMPLETED
PHASE2
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis
NCT07119918
NOT_YET_RECRUITING
PHASE3
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
NCT07172646
RECRUITING
PHASE1/PHASE2
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
NCT00540670
COMPLETED
PHASE2
Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)
NCT05741086
UNKNOWN
PHASE3
Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
NCT03004638
COMPLETED
PHASE2
Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
NCT03254446
UNKNOWN
PHASE3
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
NCT02991118
COMPLETED
PHASE3
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
NCT04164888
COMPLETED
PHASE2
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
NCT01609140
COMPLETED
PHASE2
Study of Intravenous ZMA001 in Healthy Subjects
NCT05967299
RECRUITING
PHASE1
Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound
NCT06586684
NOT_YET_RECRUITING
PHASE4
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
NCT04610892
COMPLETED
PHASE2